NasdaqGS:ONCBiotechs
BeOne Medicines (ONC) Stock May Be Rich After BRUKINSA Access Renewal
BeOne Medicines stock has produced a strong 85.8% return over the past three years, yet the current valuation checks and market multiples suggest the shares are not an obvious bargain at today’s price.
The 85.8% three year return signals that BeOne Medicines has already delivered substantial gains for long term holders, so fresh capital is now facing a very different entry point.
Recent agreements to expand access to BRUKINSA and to collaborate on RAS inhibitor development can support long...